Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 155
- Registration Number
- NCT05843188
- Locations
- 🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 72
- Registration Number
- NCT05846867
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, China
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05839470
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT05838768
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇬🇧Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Columbia University Medical Ctr, New York, New York, United States
To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
- Conditions
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Peking University
- Target Recruit Count
- 72
- Registration Number
- NCT05818982
- Locations
- 🇨🇳
Xinxiang Central Hospital of Henan Province, Xinxiang, China, Xinxiang, China
🇨🇳Beijing Cancer Hospital, Beijing, China, Beijing, China
🇨🇳First Hospital of Xiamen University Affiliated Hospital,Xiamen,China, Xiamen, China
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05799443
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT05800587
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 380
- Registration Number
- NCT05737563
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT05731518
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 29
- Registration Number
- NCT05732129
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.